HK1138581A1 - Triazolo [1, 5-a] quinolines as adenosine a3 receptor ligands - Google Patents

Triazolo [1, 5-a] quinolines as adenosine a3 receptor ligands

Info

Publication number
HK1138581A1
HK1138581A1 HK10104249.9A HK10104249A HK1138581A1 HK 1138581 A1 HK1138581 A1 HK 1138581A1 HK 10104249 A HK10104249 A HK 10104249A HK 1138581 A1 HK1138581 A1 HK 1138581A1
Authority
HK
Hong Kong
Prior art keywords
quinolines
triazolo
adenosine
receptor ligands
ligands
Prior art date
Application number
HK10104249.9A
Other languages
English (en)
Inventor
Edit Susan
Kinga Boer
Zoltan Kapui
Geza Timari
Sandor Batori
Zoltan Szlavik
Endre Mikus
Szeredi Judit Vargane
Michel Finet
Szabo Katalin Urban
Tibor Szabo
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of HK1138581A1 publication Critical patent/HK1138581A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
HK10104249.9A 2007-06-07 2010-04-29 Triazolo [1, 5-a] quinolines as adenosine a3 receptor ligands HK1138581A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0700395A HUP0700395A2 (en) 2007-06-07 2007-06-07 Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
PCT/HU2008/000063 WO2008149168A1 (en) 2007-06-07 2008-06-02 Triazolo [1, 5-a] quinolines as adenosine a3 receptor ligands

Publications (1)

Publication Number Publication Date
HK1138581A1 true HK1138581A1 (en) 2010-08-27

Family

ID=89987565

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10104249.9A HK1138581A1 (en) 2007-06-07 2010-04-29 Triazolo [1, 5-a] quinolines as adenosine a3 receptor ligands

Country Status (45)

Country Link
US (1) US8338411B2 (pl)
EP (1) EP2167470B1 (pl)
JP (1) JP5487100B2 (pl)
KR (1) KR20100031610A (pl)
CN (1) CN101679272B (pl)
AR (1) AR066873A1 (pl)
AT (1) ATE502016T1 (pl)
AU (1) AU2008259534B2 (pl)
BR (1) BRPI0812257A2 (pl)
CA (1) CA2689612A1 (pl)
CL (1) CL2008001648A1 (pl)
CO (1) CO6270233A2 (pl)
CR (1) CR11171A (pl)
CY (1) CY1111644T1 (pl)
DE (1) DE602008005589D1 (pl)
DK (1) DK2167470T3 (pl)
DO (1) DOP2009000276A (pl)
EC (1) ECSP099783A (pl)
ES (1) ES2363672T3 (pl)
GT (1) GT200900301A (pl)
HK (1) HK1138581A1 (pl)
HN (1) HN2009003357A (pl)
HR (1) HRP20110332T1 (pl)
HU (1) HUP0700395A2 (pl)
IL (1) IL202471A0 (pl)
JO (1) JO2689B1 (pl)
MA (1) MA31738B1 (pl)
ME (1) ME00958B (pl)
MX (1) MX2009013209A (pl)
MY (1) MY148654A (pl)
NI (1) NI200900210A (pl)
NZ (1) NZ581186A (pl)
PA (1) PA8782901A1 (pl)
PE (1) PE20090325A1 (pl)
PL (1) PL2167470T3 (pl)
PT (1) PT2167470E (pl)
RU (1) RU2489432C2 (pl)
SI (1) SI2167470T1 (pl)
SV (1) SV2009003420A (pl)
TN (1) TN2009000482A1 (pl)
TW (1) TWI424998B (pl)
UA (1) UA99463C2 (pl)
UY (1) UY31130A1 (pl)
WO (1) WO2008149168A1 (pl)
ZA (1) ZA200908280B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8884034B2 (en) 2009-07-08 2014-11-11 Dermira (Canada), Inc. TOFA analogs useful in treating dermatological disorders or conditions
FR3053968A1 (fr) * 2016-07-13 2018-01-19 Biomerieux Reactifs pour la protection reversible de molecules biologiques
MY195054A (en) * 2016-09-24 2023-01-05 Kbp Biosciences Co Ltd Pharmaceutical Composition Comprising Mineralocorticoid Receptor Antagonist and use Thereof
CN112384515A (zh) 2018-02-27 2021-02-19 因赛特公司 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶
JP7391046B2 (ja) 2018-05-18 2023-12-04 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
EP3818063A1 (en) 2018-07-05 2021-05-12 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
EA202191498A1 (ru) 2018-11-30 2021-08-20 Мерк Шарп энд Доум Корп. 9-замещенные производные аминотриазолохиназолина в качестве антагонистов аденозиновых рецепторов, фармацевтические композиции и их применение
MX2021007426A (es) 2018-12-20 2021-09-08 Incyte Corp Compuestos de imidazopiridazina e imidazopiridina como inhibidores de cinasa-2 de tipo receptor de activina.
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479759A (en) * 1974-11-23 1977-07-13 Lepetit Spa Heterocyclic fused derivatives of indole and quinoline
GR76063B (pl) * 1981-04-03 1984-08-03 Roussel Uclaf
ZA836701B (en) * 1982-10-01 1984-10-31 Roussel Uclaf Imidazo(1,2-a)quinolines
GB0108475D0 (en) 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds
IL158854A0 (en) * 2001-05-31 2004-05-12 Sanofi Synthelabo Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
HUP0105407A3 (en) * 2001-12-21 2004-04-28 Sanofi Aventis Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0105406A3 (en) * 2001-12-21 2003-12-29 Sanofi Aventis Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
ES2254778T3 (es) 2001-12-21 2006-06-16 Jsw-Research Forschungslabor Gmbh Triazoloquinoxalinas sustituidas con pirazolilo.
HUP0203976A3 (en) * 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
MEP19108A (en) * 2003-07-31 2010-06-10 Sanofi Aventis Aminoquinoline derivatives and their use as adenosine a3 ligands

Also Published As

Publication number Publication date
HU0700395D0 (en) 2007-07-30
UA99463C2 (en) 2012-08-27
JP2010529100A (ja) 2010-08-26
DOP2009000276A (es) 2010-01-31
GT200900301A (es) 2010-04-22
CO6270233A2 (es) 2011-04-20
IL202471A0 (en) 2010-06-30
ME00958B (me) 2012-06-20
US8338411B2 (en) 2012-12-25
US20100216786A1 (en) 2010-08-26
HN2009003357A (es) 2013-08-12
DK2167470T3 (da) 2011-06-27
ECSP099783A (es) 2010-01-29
MY148654A (en) 2013-05-15
ES2363672T3 (es) 2011-08-11
WO2008149168A8 (en) 2010-01-07
WO2008149168A1 (en) 2008-12-11
MX2009013209A (es) 2010-04-09
PT2167470E (pt) 2011-05-16
PE20090325A1 (es) 2009-04-17
KR20100031610A (ko) 2010-03-23
AU2008259534A1 (en) 2008-12-11
HRP20110332T1 (hr) 2011-06-30
JP5487100B2 (ja) 2014-05-07
CR11171A (es) 2010-04-21
JO2689B1 (en) 2013-03-03
TW200914451A (en) 2009-04-01
CN101679272B (zh) 2013-02-06
AR066873A1 (es) 2009-09-16
PL2167470T3 (pl) 2011-08-31
PA8782901A1 (es) 2009-01-23
CL2008001648A1 (es) 2008-10-10
DE602008005589D1 (de) 2011-04-28
RU2009149518A (ru) 2011-07-20
AU2008259534B2 (en) 2012-07-05
EP2167470B1 (en) 2011-03-16
SV2009003420A (es) 2010-04-26
TWI424998B (zh) 2014-02-01
SI2167470T1 (sl) 2011-06-30
CN101679272A (zh) 2010-03-24
NZ581186A (en) 2012-03-30
UY31130A1 (es) 2009-01-30
ZA200908280B (en) 2010-07-28
ATE502016T1 (de) 2011-04-15
HUP0700395A2 (en) 2009-03-02
NI200900210A (es) 2010-07-15
TN2009000482A1 (en) 2011-03-31
CA2689612A1 (en) 2008-12-11
RU2489432C2 (ru) 2013-08-10
MA31738B1 (fr) 2010-10-01
EP2167470A1 (en) 2010-03-31
CY1111644T1 (el) 2015-10-07
BRPI0812257A2 (pt) 2014-12-23

Similar Documents

Publication Publication Date Title
HK1138581A1 (en) Triazolo [1, 5-a] quinolines as adenosine a3 receptor ligands
ZA201101701B (en) Pyrrolo[2,3-d]pyrimidine compounds
ZA201202718B (en) Pyrrolo[2,3-d]pyrimidine compounds
PT2217578E (pt) Compostos de [1,2,4]triazolo[1,5-a]piridina e [1,2,4]triazolo[1,5-c]pirimidina e a sua utilização
IL204721A0 (en) Pyrrolo [2,3 - d] pyrimidin derivatives as protein kinase b inhibitors
HRP20130660T1 (en) Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
BRPI0822237A2 (pt) Compostos de imidazo [1,2-a] piridina
ZA200805354B (en) Aryl-isoxazol-4-yl-imidazo[1,5-A]pyridine derivatives
ZA201004823B (en) Novel pyrazolo [3,4-d]pyrimidine derivatives as anti-cancer agents
ZA201004368B (en) Pyrazolo [1,5-a] pyrimidines useful as jak2 inhibitors
PL2124944T3 (pl) Pochodne pirazolo[3,4-b]pirydyny jako inhibitory fosfodiesterazy
AU2008313789A8 (en) Purine derivatives as adenosine AL receptor ligands
EP2142542A4 (en) NEW IMIDAZO [4,5-B] PYRIDINE-7-CARBOXYLAMIDEAMIDE 704
PL2155712T3 (pl) 3-(imidazolilo)-pirazolo[3,4-b]pirydyny
BRPI0822239A2 (pt) Composto de pirazolo[1,5-a] pirimidina
ZA201101861B (en) Compositions with and process for methylmorpholin-substituted pyrido [2,3-d] pyrimidines
ZA200907416B (en) Pyrimido [4,5-D] azepine derivatives as 5-HT2C agonists
SI1899343T1 (sl) Halogenirani pirazolo a pirimidini postopkiuporabe kot ligand receptorjev GABA A sestavki in intermediati
EP2511276A4 (en) PYRROLO [2,3-D] PYRIMIDINE DERIVATIVE
IL206666A0 (en) N-PHENYLIMIDAZO[1,2-a]PYRIDINE-2-
IL188924A0 (en) Imidazopyridine derivatives as cannabinoid receptor ligands
IL206668A0 (en) N-PHENYLIMIDAZO[1,2-a]PYRIDINE-2-
GB0712957D0 (en) Cupholders
ZA200800354B (en) Imidazopyridine derivatives as cannabinoid receptor ligands
IL194384A0 (en) Process for preparaing 6,7-dihydro-5h-imidazo[1,5-a]pyridin-8-one

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150602